Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the quick ratio (acid-test) high or low?
The quick ratio (acid-test) of 13.89 is 134% above its 4-year average of 5.95, near the high end of its 4-year range (0.00–14.16).
As of the fiscal period ended Tuesday, June 30, 2026. 35.92% above its 12-month average of 10.22.
Reported quarterly quick ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 13.89.
QUICK RATIO (ACID-TEST)
13.89
QUICK RATIO (ACID-TEST) AVG TTM
10.22
QUICK RATIO (ACID-TEST) AVG 3Y
7.46
QUICK RATIO (ACID-TEST) AVG 5Y
N/A
QUICK RATIO (ACID-TEST) AVG 10Y
N/A
QUICK RATIO (ACID-TEST) AVG 15Y
N/A
QUICK RATIO (ACID-TEST) AVG 20Y
N/A
CURRENT VS TTM AVG
+35.92%
CURRENT VS 3Y AVG
+86.16%
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
3.35
median of 871 covered companies
CURRENT VS SECTOR MEDIAN
+314.52%
vs the sector median at left
Lexeo Therapeutics, Inc. Common Stock
Market Cap
$258.34M
Quick Ratio (Acid-Test)
13.89
TTM Avg
10.22
3Y Avg
7.46
5Y Avg
N/A
Market Cap
$256.68M
Quick Ratio (Acid-Test)
3.19
TTM Avg
3.85
3Y Avg
4.21
5Y Avg
4.14
Market Cap
$257.37M
Quick Ratio (Acid-Test)
0.93
TTM Avg
1.36
3Y Avg
5.78
5Y Avg
8.29
Market Cap
$258.73M
Quick Ratio (Acid-Test)
16.00
TTM Avg
13.11
3Y Avg
8.33
5Y Avg
7.81
Market Cap
$258.85M
Quick Ratio (Acid-Test)
11.02
TTM Avg
6.66
3Y Avg
6.10
5Y Avg
6.28
Market Cap
$262.00M
Quick Ratio (Acid-Test)
4.46
TTM Avg
8.30
3Y Avg
6.73
5Y Avg
6.78
Market Cap
$261.24M
Quick Ratio (Acid-Test)
24.26
TTM Avg
16.09
3Y Avg
10.56
5Y Avg
7.83
Market Cap
$261.28M
Quick Ratio (Acid-Test)
7.68
TTM Avg
7.37
3Y Avg
6.66
5Y Avg
5.96
Market Cap
$251.10M
Quick Ratio (Acid-Test)
27.99
TTM Avg
35.39
3Y Avg
23.13
5Y Avg
23.13
| NAME | MARKET CAP | QUICK RATIO (ACID-TEST) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Lexeo Therapeutics, Inc. Common Stock (LXEO) | $258.34M | 13.89 | 10.22 | 7.46 | N/A |
| Anika Therapeutics, Inc. (ANIK)vs › | $256.68M | 3.19 | 3.85 | 4.21 | 4.14 |
| AC Immune S.A. (ACIU)vs › | $257.37M | 0.93 | 1.36 | 5.78 | 8.29 |
| Eupraxia Pharmaceuticals Inc. (EPRX)vs › | $258.73M | 16.00 | 13.11 | 8.33 | 7.81 |
| X4 Pharmaceuticals, Inc. (XFOR)vs › | $258.85M | 11.02 | 6.66 | 6.10 | 6.28 |
| EyePoint Pharmaceuticals, Inc. (EYPT)vs › | $262.00M | 4.46 | 8.30 | 6.73 | 6.78 |
| Palisade Bio, Inc. (PALI)vs › | $261.24M | 24.26 | 16.09 | 10.56 | 7.83 |
| OraSure Technologies, Inc. (OSUR)vs › | $261.28M | 7.68 | 7.37 | 6.66 | 5.96 |
| Upstream Bio, Inc. (UPB)vs › | $251.10M | 27.99 | 35.39 | 23.13 | 23.13 |
| Scribe Therapeutics Inc. (SCTX)vs › | $264.25M | N/A | N/A | N/A | N/A |
Quick Ratio
13.89
Excludes inventory
Current Ratio
13.89
Includes inventory
Quick Ratio = (Current Assets − Inventory) / Current Liabilities
The quick ratio is a stricter liquidity measure that excludes inventory, showing the ability to meet short-term obligations with the most liquid assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | QUICK RATIO (ACID-TEST) |
|---|---|
| 2026-06-30 | 13.89 |
| 2026-03-31 | 14.16 |
| 2025-12-31 | 11.21 |
| 2025-09-30 | 7.40 |
| 2025-06-30 | 4.43 |
| 2025-03-31 | 3.42 |
| 2024-12-31 | 5.52 |
| 2024-09-30 | 5.95 |
| 2024-06-30 | 9.38 |
| 2024-03-31 | 9.16 |
| 2023-12-31 | 7.21 |
| 2023-09-30 | 1.69 |
| 2023-06-30 | 3.57 |
| 2023-03-31 | 4.47 |
| 2022-12-31 | 5.58 |
| 2022-09-30 | 0.00 |
| 2022-06-30 | 0.00 |
| 2022-03-31 | 0.00 |
